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Introduction: The reasons why research participants join clinical trials remains an area of inquiry especially in
low and middle income countries.
Methods: We conducted exit interviews with participants who took part in a trial which aimed to evaluate
whether long term prophylaxis with cotrimoxazole can be safely discontinued among adults who have been
stabilised on antiretroviral therapy (ART). Participants were all reported to be stable on ART and had been
participating in the trial for between 12 and 36 months; at the end of the trial participants were interviewed
using a semi-structured questionnaire. One of the objectives of the exit interview was to ﬁnd out what motivated
the participants to join the research.
Results: Participants gave personal reasons for joining the trial, frequently linked to their health and well-being
as well as reduction of pill burden.
Conclusion: We conclude that underlying reasons for joining clinical trials may extend beyond or can be diﬀerent
from the rationale given to the participants before enrolment by the research team. The reasons that motivate
enrolment to clinical trials and research in general require further investigation in diﬀerent settings.
Trial registration number: ISRCTN44723643.
1. Introduction
The sustained participation and cooperation of volunteers recruited
to take part in clinical trials is essential for their success. While
randomised controlled trials are considered to be the gold standard
methodology to test medical interventions [1,2], the conduct of the trial
is dependent on people's willingness to take part. There has, as a result,
been considerable interest in what motivates a person to volunteer to
take part in a trial. While Jenkins and Fallowﬁeld [3], in their
assessment of the reasons for participation in a cancer trial, concluded
that people were motivated by a desire to help others and trust in their
doctor, others have noted personal gain as an overriding motive for
taking part in some trials [4–6] or a desire to please their doctor/health
care team [7,8].
Jenkins and Fallowﬁeld [3] noted that people are more likely to
take part in a trial when there is active treatment in all trial arms. Mills
and colleagues [4] concur, observing participants' dislike of placebo or
‘no-treatment’ groups, and there are concerns about randomisation, the
research process and the chance of being placed on a no treatment arm.
A study on bladder cancer showed that patients may decline to join a
randomised trial because of their desire for eﬀective treatment [9].
However, the expected health beneﬁts may be much broader. Indeed,
several studies have found that participants anticipate improved access
to health care through taking part [5,6,10,11]. This may be particularly
important in settings where general health care provision is costly and/
or of poor quality. In addition, the participants' perceptions about a trial
may be very diﬀerent from what the research team may be emphasising
as the objective of the research [12] and their reason for participation
has previously been reported to inﬂuence their adherence to trial
medication and procedures [13].
We present in this paper data on the motivation to participate in a
clinical trial conducted in Uganda, collected through exit interviews.
2. Background
2.1. COSTOP trial
The COSTOP trial was a randomised double blind placebo con-
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trolled trial to evaluate whether long-term prophylaxis with cotrimox-
azole (CTX) can be discontinued without loss of eﬃcacy and with a
reduction in adverse drug reactions among adults who have been
stabilised on antiretroviral therapy (ART). Volunteers were adults aged
18 years and above who had stabilised on ART and had no contra-
indication to taking CTX. They were randomised to continue CTX
prophylaxis or receive a matching placebo. Participants were followed
for a minimum of 12 and maximum of 36 months. They attended
designated study clinics monthly at regular intervals; and if unwell
could attend without an appointment. The trial was conducted at
research clinics located in Entebbe and Masaka, in Uganda. Full details
of the trial have been reported elsewhere [14,15].
Participants consented to participate in the trial after receiving
detailed information about the study. This included details on study
objectives, trial duration, why the participant had been invited to take
part, trial procedures and the equal likelihood that they would be
allocated to active treatment or placebo. They were compensated for
the costs of transport according to the prevailing public transport rates
and informed that there were no direct beneﬁts for the individual.
There was no compensation for time spent at the clinic. Participants in
the trial were told that they were free to withdraw from the trial at any
time.
The investigators were concerned that a positive outcome to the
trial might be questioned if there was a possibility that the participants
may have had access to cotrimoxazole from sources outside the trial.
There was no simple test that could be applied to determine whether a
participant was on active drug, so a small qualitative study was nested
within the trial to investigate this concern; there was some evidence of
open label drug being taken by the participants. The results from the
participant interviews did not suggest that the trial results would have
been seriously compromised [16]. Subsequently, exit interviews were
conducted on all participants by ﬁeld workers independent from the
clinical intervention team to explore why they had agreed to participate
in the trial, and whether they had adhered to the allocated treatment.
This paper addresses the reasons given for joining the COSTOP trial.
3. Methods
The participant information document for COSTOP gave the pri-
mary reason for the research as determining whether stopping cotri-
moxazole would be safe for patients who were already doing well on
ART. This information was provided in the local language before
participants were asked for their consent to enrol in the study.
Following the ﬁnal study visit, all participants were invited to an exit
interview. This paper addresses the question in the survey regarding the
reason people joined the study. Participants were oﬀered seven
predeﬁned responses but were encouraged to give additional reasons.
3.1. Ethical requirements
The study was approved by the Uganda Virus Research Institute
Regulatory ethics committee and the Uganda National Council for
Science and Technology. Each participant gave written/thumb print
consent before taking part in the exit interview.
3.2. Procedure
Participants were randomised to be interviewed either by one of the
four social science ﬁeld assistants or one of the four trained peer HIV-
positive participants (in Entebbe or Masaka, the two sites where the
COSTOP trial was conducted). The interviewers were trained on the
purpose and application of a structured questionnaire that included
open and closed ended questions. They were all independent of the
clinical intervention team with the expectation that this would enhance
the willingness of participants to share information which they would
have found diﬃcult to give to the study team, for example about failure
to adhere.
Responses were analysed both by total participants and stratiﬁed by
gender and age (see Table 1), the most likely confounders. It was not
our intention to test a hypothesis, rather to describe reasons given for
joining the trial.
4. Results
Of 2180 participants enrolled into the trial 37 died before the ﬁnal
visit, 95 were lost to follow-up, 49 had withdrawn consent and six were
not interviewed at their ﬁnal study visit.
A total of 1993 (91%) participants were available for interview at
the end of the study out of the 2180 randomised participants. Of the
1993 participants, 986 (49%) were randomised to be interviewed by
peers and 1007 (51%) by the social scientists; 75% of the participants
were female and 76% were aged between 35 and 54 years.
Most volunteers gave more than one reason for joining the clinical
trial, 96%, chose at least one of the predeﬁned categories (Table 1).
Table 1
Participants' motivation for joining COSTOP trial.
Reasons given for joining trial Gender Age group (years) Total
Male Female < 35 35–54 55 or more
N % N % N % N % N % N %
Predeﬁned categories
To see if stopping cotrimoxazole is safe 341 66.2% 935 63.3% 200 65.8% 957 63.4% 119 66.8% 1276 64.0%
To get treatment 157 30.5% 538 36.4% 102 33.6% 535 35.4% 58 32.6% 695 34.9%
To improve my health 117 22.7% 286 19.4% 49 16.1% 310 20.5% 44 24.7% 403 20.2%
To help others through research 110 21.4% 238 16.1% 37 12.1% 271 17.9% 40 22.5% 348 17.0%
To get CD4/other test results 52 10.1% 201 13.6% 42 13.8% 188 12.4% 23 12.9% 253 12.7%
To try out new medicine 53 10.3% 172 11.6% 38 12.5% 161 10.7% 26 14.6% 225 11.2%
To obtain ﬁnancial beneﬁts 21 4.1% 105 7.1% 23 7.6% 88 5.5% 15 8.4% 126 6.3%
Other categories
Reduce pill burden 108 21.0% 286 19.4% 48 15.8% 305 20.2% 41 23.0% 394 19.8%
Expected better care, including past experience 43 8.4% 110 7.4% 26 8.6% 114 7.5% 13 7.3% 153 7.7%
To participate in research 8 1.6% 25 1.7% 4 1.3% 27 1.8% 2 1.1% 33 1.7%
Participant was told/encouraged to join 7 1.4% 20 1.4% 3 1.0% 19 1.3% 5 2.8% 27 1.4%
To obtain a cure 5 1.0% 14 1.0% 3 1.0% 16 1.1% 0 0.0% 19 1.0%
Because of HIV-infection 2 0.4% 16 1.1% 1 0.3% 17 1.1% 0 0.0% 18 0.9%
Personal cost of taking cotrimoxazole 1 0.2% 1 0.1% 0 0.0% 2 0.1% 1 0.0% 2 0.1%
Total assessed 515 100% 1477 100% 304 100% 1511 100% 178 100% 1993 100%
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Twenty nine per cent gave other reasons that were not among the
predeﬁned categories and only 12 (< 1%) did not give a reason. There
were some diﬀerences in the responses collected by social scientists and
peer interviewers; this could possibly have been because the trained
social scientists might have had more experience in probing for
information than the peers. Social desirability could also be a possible
explanation for the diﬀerence between the two groups.
The most common response given for joining the trial was to see if
stopping cotrimoxazole would be safe; this was followed by a desire to
get treatment for their illness. To improve health and reduce pill burden
were other frequently reported reasons. Older people were more likely
than younger participants to mention altruistic reasons and the desire
to further improve their health through their participation. There were
no major diﬀerences in the reasons given by men and women although
there was a suggestion that more women joined the trial to receive
treatment. There was some evidence of diﬀerences in response accord-
ing to the category of interviewer; those interviewed by social scientists
were more likely to give more than one reason than those interviewed
by peer interviewers for joining the study, namely 43.2% and 33.3%.
Participants interviewed by social scientists more often mentioned ‘to
see if cotrimoxazole is safe, 68.7% versus 59.3%’ and ‘to get treatment,
41.4% versus 28.2%.
5. Discussion
In addition to the primary question of assessing whether partici-
pants adhered to the study protocol the exit interview addressed a
number of other issues including why the participants agreed to join the
COSTOP trial. The main reasons given for participation were personal
beneﬁt, safety of discontinuing cotrimoxazole and to improve health
and access care.
In addition to the anticipated responses, predeﬁned by the research
team, several other reasons were given. The most common of these
were to reduce pill burden and the expectation of better care when
obtained at a research centre (often based on past experience with the
research group).
Other studies have shown that the ability to comprehend study
information on account of a lack of clarity of the information provided,
can be a barrier to participation in research. A study conducted in the
United Kingdom, where formal literacy would not be expected to be a
common problem in the general population, showed that health literacy
varies between participants: at least a third of the older adults had some
diﬃculty in understanding basic health related information [17].
In sub-Saharan Africa where literacy levels remain low in some
populations, researchers have tried to improve the understanding of
study information, but this remains a challenge [18,19].
Participant information requires translation into the local language
to enable comprehension of the research and health terms used in
research, and diﬀerent vernaculars may be spoken at one study site
[20]. Information needs to be simple and avoid ambiguity [12]. These
principles are in keeping with Good Clinical Practice guidelines
[21,22].
Access to good health care was an important motivation for taking
part in the COSTOP trial. The public health services in Uganda still face
limitations with respect to basic infrastructure, staﬀ numbers and
supplies [23]. The local improvements often associated with clinical
research with regards to systems, expertise and staﬀ attitudes may lead
to improvement in the health outcomes for the research participants
and the other people in the setting where research is being conducted
[24]. Volunteers participating in the COSTOP trial recognised and
appreciated this.
Although gender diﬀerences in relation to health seeking behaviour
patterns sometimes occur [25], in this trial there was little evidence of
diﬀerences in response.
Our study had some limitations. Participants may have misunder-
stood some of the questions; as these may have had diﬀerent meanings
for diﬀerent people. For example, the reason, “to see if stopping
cotrimoxazole is safe” could be regarded as a research reason or a
personal reason. It is also possible that some volunteers may have
simply repeated the rationale given to them during the consent process
rather than providing their own views. The majority of volunteers
however, gave more than one reason for joining the trial which suggests
that personal expectations have been expressed. The ﬁndings of this
study may not be generalisable to all clinical trial settings however the
trial did address both safety and eﬃcacy endpoints and could be
considered as typical of many such trials conducted in lower or middle
income countries.
6. Conclusion
Participants join trials for various reasons. Participants of the
COSTOP trial provided responses suggesting that their motivation
may extend beyond or can be diﬀerent from the rationale given to
them before enrolment. This reﬂects the importance that researchers
and sponsors should attach to understanding the culture and socio-
economic context of the potential volunteers and their setting.
Providing on-going study information to the participants by the
research teams conducting clinical trials, particularly for trials that last
for more than a year, is important. A participant may become uncertain
about the basis of the investigation and will inevitably be most
concerned about their health and wellbeing. Understanding underlying
reasons for joining clinical trials and research in general may require
investigation in diﬀerent populations particularly in low and middle
income countries [11]. There is still need for more research to under-
stand better how cultural and socio-economic factors inﬂuence parti-
cipation in research and to what extent participants may agree to
enrolment simply because they have been asked to join.
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